SIROOP Registry - A Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated With SIROlimus Or Paclitaxel Eluting Balloon Catheters
SIROOP Registry - A Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated With SIROlimus Or Paclitaxel Eluting Balloon Catheters
The purpose of the SIROOP Registry is to retrospectively and prospectively collect baseline, clinical and procedural characteristics of patients who have undergone PCI and are treated with either currently available sirolimus or paclitaxel coated DCBs (see Table 1), irrespective of clinical presentation as well as to prospectively collect data about their clinical outcomes. Outcomes will be compared in different clinical subgroups. The impact of current DCBs in different clinical settings and coronary artery lesions on cardiovascular outcomes will be assessed.
Objectives in detail:
To evaluate procedural success, efficacy, performance and clinical outcomes among various patient cohorts, who undergo PCI using currently available DCBs:
To describe procedural and clinical performance of various DCB, either alone or in combination with other stent and coronary scaffold devices
To identify optimal strategies for lesion preparation in cases treated with DCB
To identify possible predictors for TLR after treatment with DCB
To describe early and late angiographic and OCT-findings among coronary artery disease (CAD) patients treated with DCB and/or various metallic stent and scaffold devices
To evaluate the impact of different antithrombotic regimens on patient's clinical outcomes
To study procedural and clinical outcomes among CAD patients requiring hemodynamic support using mechanical devices.
To describe economic implications (cost-effectiveness) of various interventional treatments for CAD.
Inclusion Criteria:
Exclusion Criteria:
florim.cuculi@luks.ch+41412052134
matthias.bossard@luks.ch+41412051477